Information, not a decision

Myeloproliferative neoplasms: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 12 Nov 2026

Open trials (237)

NCT03589729	Phase 2	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Recruiting
NCT06351631	Phase 3	A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	Recruiting
NCT06303193	Phase 1/2	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	Recruiting
NCT07357727	Phase 3	A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)	Recruiting
NCT06523556	Phase 1/2	Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia	Recruiting
NCT04877522	Phase 4	Asciminib Roll-over Study	Recruiting
NCT05554406	Phase 2	Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)	Recruiting
NCT07623161	Phase 3	A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib	Recruiting
NCT07623200	Phase 3	A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia	Recruiting
NCT07468916	Phase 2	Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia	Not yet recruiting
NCT07722611	Phase 2/3	A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).	Recruiting
NCT06150157	Phase 1	A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms	Recruiting

225 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

No phase 3 trial in this list ended in the last 90 days.

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 12 Nov 2026

https://frontlightresearch.com/en/doctor/myeloproliferative-neoplasms/tumor-board